An interventional study of Home blood pressure apparatus and Clinic blood pressure in Hypertension, Cardiovascular Diseases and Kidney Transplant; Complications, sponsored by Oslo University Hospital. Terminated at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.
Sponsored by Oslo University Hospital · Not applicable, Interventional, and Treatment
Randomized controlled study of home blood pressure monitoring in kidney transplant recipients.
Adult kidney transplant recipients (n=458) will be randomized 1:1 to standard-of-care (SOC) or home blood pressure measurement (HBPM). The SOC group will target office blood pressure \<130/80 mmHg. The HBPM group will measure BP at home, twice morning and evening for (3-)7 days before routine clinical visits (ideally 28 measurements); the mean value from day 2-7 is used; target home mean BP is \< 125/80 mmHg.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's enrollment of 21 is below the median of 90 across 4,995 interventional studies indexed under Hypertension.
Browse Hypertension studies →Oslo University Hospital is the lead sponsor of 810 studies on the registry; 148 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Any or more of the following at the baseline clinic
Exclusion Criteria:
Clinical blood pressure measured at regular visits
Other: Clinic blood pressure
Home blood pressure measured daily for 1 week before regular clinical visits
Device: Home blood pressure apparatus
Target \<125/80 mmHg
Target \<130/80 mmHg
Office systolic blood pressure (BP)
As reported to Norwegian Renal Registry
Time frame: 1 year
Office diastolic BP
As reported to Norwegian Renal Registry
Time frame: 1 year
Proportion with BP below target (office BP <130/80 mmHg)
As reported to Norwegian Renal Registry
Time frame: 1 year
Number of BP lowering medications
As reported to Norwegian Renal Registry
Time frame: 1 year
Treatment satisfaction
According to study-specific questionnaire in Norwegian. Scores of 1-5, higher scores indicating higher satisfaction.
Time frame: 1 year
Concentration of plasma creatinine
As reported to Norwegian Renal Registry
Time frame: 1 year
Urine protein/creatinine ratio
As reported to Norwegian Renal Registry
Time frame: 1 year
Number of patients with cardiovascular events
As reported to the Norwegian Renal Registry. Safety endpoint. Includes myocardial infarction, stroke, coronary artery bypass grafting or -angioplasty, other cardiac surgery.
Time frame: 1 year
Number of participants with kidney graft loss
As reported to the Norwegian Renal RegistrySafety. Safety endpoint. Includes return to dialysis or re-transplant.
Time frame: 1 year
Number of participants with kidney graft rejection
As reported to Norwegian Renal Registry. Safety endpoint.
Time frame: 1 year
Number of deaths
As reported to Norwegian Renal Registry. Safety endpoint
Time frame: 1 year
Overall quality of life
According to study-specific questionnaire in Norwegian. Scores of 1-5, higher scores indicating higher quality of life.
Time frame: 1 year
Hypotensive episodes
According to study-specific questionnaire in Norwegian. Self-reported safety endpoint. Questions about A) Pre-syncope (3 categories: never; a few; montly or more); B) Syncope (3 categories: never; once; multiple). C) If syncope, free text if any trauma was experienced.
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oslo University Hospital